<?xml version="1.0" encoding="UTF-8"?>
<rootTag>
<Award>
<AwardTitle>SBIR Phase II:  Development of Osteogenic Pedicle Screws for Posterolateral Spinal Fusion</AwardTitle>
<AGENCY>NSF</AGENCY>
<AwardEffectiveDate>09/15/2017</AwardEffectiveDate>
<AwardExpirationDate>08/31/2020</AwardExpirationDate>
<AwardTotalIntnAmount>732992.00</AwardTotalIntnAmount>
<AwardAmount>732992</AwardAmount>
<AwardInstrument>
<Value>Standard Grant</Value>
</AwardInstrument>
<Organization>
<Code>07070000</Code>
<Directorate>
<Abbreviation>ENG</Abbreviation>
<LongName>Directorate For Engineering</LongName>
</Directorate>
<Division>
<Abbreviation>IIP</Abbreviation>
<LongName>Div Of Industrial Innovation &amp; Partnersh</LongName>
</Division>
</Organization>
<ProgramOfficer>
<SignBlockName>Muralidharan Nair</SignBlockName>
<PO_EMAI>mnair@nsf.gov</PO_EMAI>
<PO_PHON>7032927059</PO_PHON>
</ProgramOfficer>
<AbstractNarration>The broader impact/commercial potential of this project relates to the&lt;br/&gt;development of non-pharmacological interventions capable of improving clinical&lt;br/&gt;outcomes following spinal fusion surgery. Between 1998 and 2008, the annual&lt;br/&gt;number of spinal fusion surgeries increased 137% from 174,223 to 413,171 and the&lt;br/&gt;national bill for spinal fusion increased 7.9-fold. The greatest risk in spinal fusion&lt;br/&gt;procedures is failure to fuse, which can be particularly troublesome in high risk&lt;br/&gt;patients. Failure to fuse leads to poor surgical outcomes for patients and may result in&lt;br/&gt;chronic pain, secondary surgical procedures, reduced productivity, and/or permanent&lt;br/&gt;disability. In addition, failure to fuse results in greater clinical burden for physicians&lt;br/&gt;and increased cost per patient for payers. Lumbar fusions, in particular, have a&lt;br/&gt;cumulative reoperation rate of 19% over the 11 years following the initial procedure&lt;br/&gt;(BCC Research, 2010). The present project could result in the identification of new&lt;br/&gt;surgical devices and techniques capable of improving surgical outcomes, reducing&lt;br/&gt;complications, and eliminating costs associated with unsuccessful surgery. Osteogenic&lt;br/&gt;surgical device and techniques developed in the present project may also be used to&lt;br/&gt;accelerate bone healing and improve clinical outcomes following fractures of the skull,&lt;br/&gt;face, and long bones.&lt;br/&gt;&lt;br/&gt;This Small Business Innovation Research (SBIR) Phase 2 project is to&lt;br/&gt;demonstrate in an animal model that osteogenic spinal instrumentation accelerates&lt;br/&gt;new bone formation and improves the rate of posterolateral fusion compared to&lt;br/&gt;clinically-accepted best practices in spinal fusion surgery. Innovative osteogenic spinal&lt;br/&gt;instrumentation (pedicle screws, rods, etc.) facilitates both mechanical stabilization of&lt;br/&gt;the spine and focused delivery of fusion-stimulating direct electric current (DC) at the&lt;br/&gt;fusion site. Application of therapeutic stimuli via selectively anodized pedicle screws&lt;br/&gt;accelerates the rate at which new bone is formed in critical regions of the spine such&lt;br/&gt;as the zygapophyseal joint and lateral gutter. The propensity of newly formed bone to&lt;br/&gt;create a robust, biomechanically sound fusion of adjacent vertebrae is also increased&lt;br/&gt;under osteogenic stimulation. Phase I results demonstrate that selectively-anodized&lt;br/&gt;electroactive pedicle screws effectively deliver focused osteogenic stimuli to key&lt;br/&gt;regions of the lumbar spine critical to spinal fusion. Results provide computational&lt;br/&gt;evidence for the technological and clinical success of novel osteogenic&lt;br/&gt;instrumentation in spinal fusion surgery. Phase II will confirm that the system of&lt;br/&gt;electroactive spinal instrumentation has the potential to accelerate bone growth and&lt;br/&gt;improve post-surgical fusion outcomes compared to gold-standard interventions&lt;br/&gt;utilizing a clinically relevant large animal model.</AbstractNarration>
<MinAmdLetterDate>09/20/2017</MinAmdLetterDate>
<MaxAmdLetterDate>09/20/2017</MaxAmdLetterDate>
<ARRAAmount/>
<TRAN_TYPE>Grant</TRAN_TYPE>
<CFDA_NUM>47.041</CFDA_NUM>
<NSF_PAR_USE_FLAG>1</NSF_PAR_USE_FLAG>
<FUND_AGCY_CODE>4900</FUND_AGCY_CODE>
<AWDG_AGCY_CODE>4900</AWDG_AGCY_CODE>
<AwardID>1738517</AwardID>
<Investigator>
<FirstName>Matthew</FirstName>
<LastName>MacEwan</LastName>
<PI_MID_INIT/>
<PI_SUFX_NAME/>
<PI_FULL_NAME>Matthew MacEwan</PI_FULL_NAME>
<EmailAddress>matt.macewan@osteovantage.com</EmailAddress>
<PI_PHON>4795712592</PI_PHON>
<NSF_ID>000622447</NSF_ID>
<StartDate>09/20/2017</StartDate>
<EndDate/>
<RoleCode>Principal Investigator</RoleCode>
</Investigator>
<Institution>
<Name>OsteoVantage, Inc</Name>
<CityName>Fayetteville</CityName>
<CountyName>WASHINGTON</CountyName>
<ZipCode>727016948</ZipCode>
<PhoneNumber>4795712592</PhoneNumber>
<StreetAddress>535 W Research Center Blvd</StreetAddress>
<StreetAddress2><![CDATA[Ste 135, M/S 2600]]></StreetAddress2>
<CountryName>United States</CountryName>
<StateName>Arkansas</StateName>
<StateCode>AR</StateCode>
<CONGRESSDISTRICT>03</CONGRESSDISTRICT>
<CONGRESS_DISTRICT_ORG>AR03</CONGRESS_DISTRICT_ORG>
<ORG_DUNS_NUM>078399483</ORG_DUNS_NUM>
<ORG_LGL_BUS_NAME>OSTEOVANTAGE, INC</ORG_LGL_BUS_NAME>
<ORG_PRNT_DUNS_NUM/>
</Institution>
<Performance_Institution>
<Name><![CDATA[OsteoVantage, Inc]]></Name>
<CityName/>
<CountyName>WASHINGTON</CountyName>
<StateCode>AR</StateCode>
<ZipCode>727016948</ZipCode>
<StreetAddress/>
<CountryCode>US</CountryCode>
<CountryName>United States</CountryName>
<StateName>Arkansas</StateName>
<CountryFlag>1</CountryFlag>
<CONGRESSDISTRICT>03</CONGRESSDISTRICT>
<CONGRESS_DISTRICT_PERF>AR03</CONGRESS_DISTRICT_PERF>
</Performance_Institution>
<ProgramElement>
<Code>5373</Code>
<Text>SBIR Phase II</Text>
</ProgramElement>
<ProgramReference>
<Code>4080</Code>
<Text>ADVANCED COMP RESEARCH PROGRAM</Text>
</ProgramReference>
<ProgramReference>
<Code>5373</Code>
<Text>SMALL BUSINESS PHASE II</Text>
</ProgramReference>
<ProgramReference>
<Code>8035</Code>
<Text>Hardware Devices</Text>
</ProgramReference>
<ProgramReference>
<Code>8038</Code>
<Text>Biotechnology</Text>
</ProgramReference>
<ProgramReference>
<Code>9150</Code>
<Text>EXP PROG TO STIM COMP RES</Text>
</ProgramReference>
<Appropriation>
<Code>0117</Code>
<Name>NSF RESEARCH &amp; RELATED ACTIVIT</Name>
<APP_SYMB_ID>040100</APP_SYMB_ID>
</Appropriation>
<FUND_OBLG>2017~732992</FUND_OBLG>
</Award>
</rootTag>
